The results from three Phase III studies of the experimental medication Ocrevus™ (ocrelizumab) were published in the December 21, 2016 online issue of the New England Journal of Medicine (NEJM). […]
Read News ArticleSearch Results for:
FDA Extends Review of Ocrevus™ (ocrelizumab)
On December 20, 2016, Genentech, a member of the Roche group, announced that the United States Food and Drug Administration (FDA) had extended the review period of Ocrevus™ (ocrelizumab) for […]
Read News ArticleClinical Trials Search, powered by Antidote
What are Clinical Trials? Clinical trials are scientific studies that test the safety and effectiveness of new treatments for MS and other diseases. They often use human subjects. They are […]
Read News ArticleHighlights from the 2016 ECTRIMS Annual Meeting
More than 9,000 clinicians and researchers attended the 2016 meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in London, England. This year’s conference took place […]
Read News ArticleBecome a Monthly Donor
Just $25 per month will provide cooling vests for two people with MS.
Read News ArticleTributes
A tribute gift to MSAA is a thoughtful way to honor or memorialize someone whose life has been affected by MS.
Read News ArticleThe Motivator: Summer/Fall 2016 – View Digital Edition
View the Digital Version of MSAA’s Publication – The Motivator – Summer/Fall 2016.
Read News ArticleThe Motivator: Summer/Fall 2016 – Download PDF
Download the PDF of MSAA’s Publication: The Motivator – Summer/Fall 2016.
Read News ArticleSpread the Word
Three books from MSAA’s free Lending Library are featured.
Read News ArticleThoughts about Giving: Continuing Our Opportunities to Give
MSAA’s new Vice President of Development is introduced.
Read News Article